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Abstract Approximately 30 % of colorectal carcinomas
develop via the serrated neoplasia pathway characterized
by widespread DNA methylation and frequent BRAF
mutation. Serrated polyps represent a heterogeneous group
of polyps which are the precursor lesions to serrated
pathway colorectal carcinomas. The histological classifi-
cation of serrated polyps has evolved over the last two
decades to distinguish three separate entities: hyperplastic
polyp, sessile serrated adenoma (SSA), and traditional
serrated adenoma (TSA). The malignant potential of SSAs
and TSAs has been clearly demonstrated. SSAs are more
challenging to detect by colonoscopy and are likely to
account for some interval carcinomas of the proximal
colon. Serrated polyposis syndrome is now widely recog-
nized as conferring a high risk of colorectal carcinoma
although its cause remains elusive. The current under-
standing of the actual malignant potential of each serrated
polyp subtype is still limited due to the lack of large-scale
prospective studies. Patient management guidelines have
been recently updated although high-level evidence to
support them is still required.
Keywords Serrated polyps  Colorectal neoplasia 
Colonoscopy  Histology  Molecular pathology  Patient
management
Introduction
Colorectal carcinoma (CRC) is one of the most common
cancers worldwide. Virtually all CRCs originate from a
precursor benign polyp, which makes this cancer potentially
preventable by appropriate screening colonoscopy pro-
grams in patients at increased risk. Until approximately
1990, colorectal polyps were classified into two groups:
adenomatous polyps (conventional adenomas) with a well-
recognized potential for malignant transformation and
hyperplastic (or ‘metaplastic’) polyps thought to have no
risk of malignant transformation. While conventional ade-
nomas are still considered to represent the precursor lesions
of the majority of CRC, the group of polyps previously
called ‘hyperplastic polyps’ has now been divided in vari-
ous subtypes with respect to their morphologic appearance,
molecular alterations, and risk of malignant transformation.
Over the last 20 years, our understanding of CRC path-
ogenesis has evolved from the concept of a single disease
progressing through a sequence of morphologic and genetic
alterations [1] to the concept of molecular heterogeneity
and tumor uniqueness [2]. CRC is currently classified into
subgroups of tumors which share similar molecular
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alterations in correlation with morphologic appearance and
clinical features [3, 4]. Such classifications can become
more and more complex as the number of classifiers
increases to reach a complete set of characteristics that
underlies the concept of a unique tumor arising in a unique
individual. Therefore a meaningful classification should
retain parameters with clinical consequences for patient
management such as prevention, treatment, and surveil-
lance. The nature of the precursor polyp is an essential
classifier of CRC because each tumor is thought to develop
from a unique benign polyp with its own set of morphologic
and molecular characteristics. The heterogeneity of CRC
translates to a certain extent into the multiplicity of pre-
cursor polyp subtypes that we have only recently started to
understand. Conventional adenomas are the precursor
lesions to CRCs developing via the traditional adenoma–
carcinoma pathway characterized by chromosomal insta-
bility (except in patients with Lynch syndrome). Serrated
polyps are the precursors of CRCs developing through the
serrated neoplasia pathway characterized by BRAF muta-
tion, CpG island methylator phenotype (CIMP), with or
without microsatellite instability (MSI).
Serrated polyps represent a group of polyps with various
recently recognized subtypes associated with different
colonoscopic appearance, histology, molecular alteration,
and risk of progression to malignancy: hyperplastic polyp
(HP), sessile serrated adenoma (SSA), and traditional ser-
rated adenoma (TSA). In this review, we will present our
current knowledge about serrated polyps and the chal-
lenges that pathologists, gastroenterologists, and molecular
biologists still face in understanding the clinical signifi-
cance of these lesions for the patients.
Prevalence and risk factors for serrated polyps
The prevalence of serrated polyps in the general population
has been evaluated in autopsy studies to range from 13 to
40 % [5, 6]. In a prospective population-based colonoscopy
study, Forsberg et al. [7] reported that 21 % of asymptomatic
individuals had at least one hyperplastic polyp identified by
colonoscopy. Studies of the prevalence and clinical features
of serrated polyp subtypes are only meaningful if they were
conducted after about 2005 when the entity of SSA was
established and started to be recognized in the pathology
community [8]. Prior to that time, most serrated polyps were
considered to be HPs and epidemiological studies have
limited utility in light of current knowledge. The prevalence
of SSAs and TSAs in patients undergoing colonoscopy
appears to be influenced by the patient population, endoscopy
technique, and pathologic interpretation (Table 1). The true
prevalence in different populations will become established
as endoscopic detection and pathologic interpretation of
these lesions become more standardized. In all series, SSAs
were approximately ten times more common than TSAs.
The risk factors for SSAs and TSAs are still being
defined. There is strong evidence from case control studies
that smoking is associated with an increased risk of SSAs
with an odds ratio of approximately 7 [9, 10]. This is sup-
ported by data showing an association between smoking and
CRCs which are CIMP-high (high level of CIMP) and
harbor BRAF mutation [11]. There is also strong evidence
that there is a genetic predisposition to serrated neoplasia
and that the genes involved may be more common in Cau-
casians [12, 13]. The genetic predisposition may be a con-
tinuum involving a number of genes, each of moderate
effect, which interact with environmental factors such as
smoking. At one end of the spectrum may be serrated pol-
yposis whilst other individuals may have a few SSAs in the
proximal colon and an increased lifetime risk of CIMP-high
BRAF-mutated CRC [14, 15]. A recent population-based
study showed an increased cancer predisposition in family
members of patients with BRAF-mutated CRC [16]. There is
likely to be overlap between the environmental and genetic
risk factors for SSAs and conventional adenomas as indi-
viduals with SSAs are more likely to also have conventional
adenomas as well as multiple serrated polyps [17–19].
Definition and histological classification of serrated
polyps
In contrast to conventional adenomas, serrated polyps have
in common a ‘saw-tooth’ appearance of the colonic crypts.
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This pattern is thought to result from decreased apoptosis
and increased senescence of epithelial cells along the
crypts [20]. According to the latest World Health Organi-
zation (WHO) classification published in 2010 [21], ser-
rated polyps are now categorized into three main subtypes:
hyperplastic polyps, sessile serrated adenoma/polyps
without or with cytological dysplasia, and traditional ser-
rated adenomas. The terms sessile serrated adenoma and
sessile serrated polyp are both synonyms and acceptable in
diagnostic use. An easy conceptual way to define and dif-
ferentiate these subgroups is based on differences in loca-
tion of the proliferation zones within the serrated crypts in
each subgroup [22, 23]. In HP, the expanded proliferation
zone is located at the base of the crypts (like in normal
crypts) and cells mature towards the surface symmetrically.
In SSA, the proliferation zone is shifted from the base to
the side of the crypts resulting in maturation of epithelial
cells towards the surface and the base, leading to crypt base
dilatation. In TSA, the proliferation zone is represented by
multiple small ectopic crypt formations from the side of the
original crypts and along the newly formed villous pro-
jections of the polyp [23].
The main features defining each serrated polyp subtype
are reported in Table 2 and Fig. 1. HPs are further subdi-
vided into microvesicular HP and goblet cell HP. However,
this distinction is mostly of academic interest at the present
time and is usually not reported by pathologists. HPs rep-
resent the most innocuous subtype of serrated polyps but
there are still unresolved questions on their possible evo-
lution to more advanced polyps. It is unclear whether some
microvesicular HP can progress to SSA or whether SSA
can arise ab initio without an initial step of microvesicular
HP. With the high prevalence of diminutive (B5 mm)
microvesicular HP found in the distal colorectum con-
trasting with the rarity of CRC with features of serrated
neoplasia pathway diagnosed in this location, it is unlikely
that distally located HPs have any malignant potential.
Moreover, the significance of goblet cell HP is poorly
understood; some authors have suggested that it may rep-
resent the precursor lesion of TSA [24, 25]. SSA is defined
by a sessile polyp with abnormal crypt architecture and
abnormal proliferation but no dysplasia. However, dys-
plasia can arise in SSA and usually appears as a sharply
demarcated area of the polyp with cytological dysplasia
resembling conventional adenoma. These polyps were
often reported as mixed polyps in the past.
With the advent of this new nomenclature, prior termi-
nologies such as ‘serrated adenoma’, ‘variant HP’, or
‘mixed polyp’ should no longer be used. In most cases,
pathologists are able to classify serrated polyps in each of
these categories. However, there are a few situations
whereby a definite histological diagnosis can be difficult to
achieve. This can be secondary to an unusual appearance of
a polyp that displays features of more than one polyp
subtype. In this regard, the 2010 WHO classification defi-
nition states that if as few as two or three contiguous crypts
demonstrate features of SSA in an otherwise HP-appearing
polyp, the polyp should be classified as an SSA. Moreover,
if a polyp displays an overall growth pattern of a TSA with
ectopic crypt formations, but with a predominance of





TSA SSA SSA with cytological dysplasia
Proportion [19, 21,
37, 99, 116]
40–50 % 20–30 % 2–5 % 15–25 % 2–5 %
Predominant
location
























cells in crypt base
No dysplasia No dysplasia Eosinophilic cells with
pencillate nuclei









KRAS mutation BRAFV600E mutation BRAFV600E mutation
BRAFV600E mutation CIMP CIMP
Microsatellite instability or
TP53 alteration
Malignant potential Very low Low High High Very high
HP hyperplastic polyp, SSA sessile serrated adenoma, TSA traditional serrated adenoma
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goblet cells (as opposed to tall eosinophilic cells with
pencillate nuclei), the polyp should be classified as TSA. It
should be noted that these definition criteria are based on a
low level of biological evidence. Confusion also occurs
when a polyp with an overall growth pattern of SSA dis-
plays cytologic features of TSA. A descriptive report is
Fig. 1 Histological appearances of various subtypes of serrated
polyps. Hyperplastic polyps (a, b) are characterized by elongated
crypts with overall preserved architecture. The serrated (‘saw-tooth’)
appearance is on the upper part of the crypts with narrow bases. Note
that the serration is more subtle in goblet cell hyperplastic polyps
(b) compared to microvesicular hyperplastic polyps (a). Sessile
serrated adenomas (c, d) demonstrate abnormal crypt architecture
with broad bases and dilation of the crypts due to the shift of the
proliferation zones from the base to the side of the crypts. Note the
abundant mucus on the surface and in the crypt lumens corresponding
to the mucus cap at colonoscopy. Sessile serrated adenoma can
develop cytological dysplasia (right part of e) with complex crypt
architecture and cytological atypia. Traditional serrated adenomas
(f) are commonly exophytic polyps displaying villous projections
with ectopic crypt formations and lined by cells with eosinophilic
cytoplasm
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recommended until a better understanding of these lesions
is known. Another common difficult situation arises when
the polyp is obliquely sectioned, not showing the crypt
bases to be able to distinguish HP from SSA. If deeper
sections do not help, a diagnosis of ‘non-dysplastic serrated
polyp, unclassified’ is recommended. Finally, it may be
impossible for the pathologist to distinguish between
piecemeal resection of an SSA with cytological dysplasia
and the co-occurrence of separate conventional adenoma
and SSA when information on the number of polyps sub-
mitted in one specimen bottle is lacking. Communication
with the gastroenterologist should resolve this problem.
The issue of interobserver reproducibility among
pathologists (including gastrointestinal pathologists) to
diagnose SSA has been addressed by several groups,
showing poor to moderate kappa values (0.14–0.55
between SSA and other polyps) [26–30]. It is anticipated
that an increase in awareness among the pathology
community and the release of the 2010 WHO criteria [21]
will result in improvement of the reproducibility of serrated
polyp diagnosis [31].
Molecular features of serrated polyps
Molecular data has complemented the evolution of serrated
polyp nomenclature (Fig. 2). The most characteristic and
well-studied molecular changes in serrated polyps are the
mitogen activated protein kinase (MAPK) pathway acti-
vation through mutation of the BRAF oncogene and
development of the CIMP. The importance of increased
Wnt pathway signaling in serrated lesions has been deba-
ted, but may be important at the transition to dysplasia.
Disruption of TP53 may also be involved in the progres-
sion of serrated polyps. Current challenges are to determine
why BRAF is almost exclusively mutated in serrated
Fig. 2 Pathways of serrated neoplasia. Oncogenic BRAF mutation is
detected in the earliest serrated lesions. Methylation changes are also
established early in serrated polyp development, although frank CpG
island methylator phenotype (CIMP) using highly specific markers
may not be evident until the sessile serrated adenoma stage. Wnt
pathway deregulation is more common in serrated polyps with
cytological dysplasia, as is MLH1 DNA methylation which leads to
microsatellite instability (MSI) and repeat tract mutation in genes
such as TGFbRII. The TP53 gene is more commonly mutated in
microsatellite stable (MSS) CRCs. Progression to either MSS or MSI
CRC may occur through a traditional serrated adenoma intermediate
(dashed arrows), although this is less common and not well
documented. Progression to traditional serrated adenoma from goblet
cell hyperplastic polyp or from conventional adenoma (dashed
arrows) has also been hypothesized but not well studied
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polyps, whether this mutation directs polyp architecture,
and whether it is sufficient to initiate polyp growth. A
further challenge is to better understand the timing and
targets of the CIMP, including which genes become
methylated during polyp initiation versus progression.
MAPK pathway activation
The MAPK signaling pathway is commonly altered in CRC
and precursor lesions through oncogenic mutation of either
the BRAF or KRAS genes. These mutations are mutually
exclusive and demonstrate a striking specificity for serrated
polyp subtype [19, 32, 33]. BRAF is mutated with
increasing frequency in serrated aberrant crypt foci (62 %)
[34], microvesicular HP (70–76 %) [19, 35], borderline
SSA (80 %) [36], SSA (61–100 %) [19, 36–40], and SSA
with cytological dysplasia or invasive cancer (64–100 %)
[40, 41], supporting the concept of a histologic continuum.
BRAF is uncommonly mutated in goblet cell HP. Rather,
KRAS is mutated in approximately 50 % of goblet cell HP
but rarely in microvesicular HP or SSA [19].
MAPK pathway activation is also common in TSA, but
the relative proportion of BRAF versus KRAS mutation
varies widely in different studies, probably reflecting dif-
ferences in histological classification or small sample size.
BRAF mutation rates in TSA range from 27 to 55 % [25,
42, 43] compared to 29–46 % for KRAS mutation [25, 42].
Refinement of the histological features of TSA will
increase the consistency of diagnosis and therefore will
clarify the involvement of the MAPK pathway in this
uncommon polyp subtype.
CpG island methylator phenotype
The CpG island methylator phenotype (CIMP) describes
the coordinate hypermethylation of multiple CpG dinu-
cleotide clusters called CpG islands. These CpG islands
often reside in gene promoter regions where aberrant DNA
hypermethylation frequently correlates with silencing of
the downstream gene. The phenotype targets many hun-
dreds of CpG islands; however, the specific gene promoters
involved and whether the associated genes become
silenced and play a role in the serrated pathway require
further investigation.
In CRC, CIMP is highly correlated with BRAF mutation.
Rates of CIMP in serrated polyps vary depending on the
marker panel used to identify the phenotype, but usually
segregate with BRAF mutation. CIMP has been reported in
47–73 % of microvesicular HP, 70–76 % of SSA, and
80 % of SSA with cytological dysplasia [35, 44], sug-
gesting that high levels of aberrant DNA methylation are
established early in the serrated pathway. In fact, specific
DNA methylation events have even been detected in
histologically normal colorectal mucosa and this correlated
with the presence of serrated polyps elsewhere in the bowel
[45]. CIMP has been less well studied in TSA, but may
occur in up to 79 % of cases [35]. TSA with a KRAS
mutation may have lower rates of CIMP compared to
those with a BRAF mutation, but this requires further
investigation.
Other than specific CIMP panel markers, many hundreds
of other gene promoters become hypermethylated in ser-
rated polyps as part of this phenotype. Dhir et al. [46]
recently showed accumulation of methylation events with
progression of serrated lesions. An average methylation
score was determined on the basis of 17 non-CIMP gene
promoters which increased from HP to SSA, with highest
scores in SSA with cytological dysplasia. The MLH1,
CDX2, and TLR2 genes were specifically methylated in
SSA and SSA with cytological dysplasia, but not in HP or
conventional adenomas. MLH1 silencing is important for
progression of a proportion of serrated polyps to cancers
showing microsatellite instability. The p16 gene is a cell
cycle inhibitor. Methylation-induced silencing of p16
allows escape from BRAF-induced senescence and also
occurs with increasing frequency with neoplastic progres-
sion [47].
Wnt signaling pathway
The Wnt signaling pathway plays an important role in the
initiation of conventional adenomas, usually through
mutation and deletion of the APC tumor suppressor gene. A
potential role in the progression of serrated polyps is more
controversial. Wnt is a ligand that binds frizzled receptors
on the cell membrane, which then signals to stabilize the
APC–Axin–GSK3b degradation complex. When APC is
silenced, the transcription factor b-catenin is no longer
degraded by this complex, but rather accumulates in the
cell nucleus, complexing with Tcf/lef to activate tran-
scription of downstream targets that promote oncogenesis.
Immunohistochemistry for b-catenin can be used to indi-
cate alteration of Wnt signaling. The normal staining pat-
tern in colonocytes is membranous, compared to nuclear
when b-catenin is abnormally stabilized. Altered immu-
nostaining is seen with increasing frequency with serrated
polyp progression, although wide variability has been
reported [40, 41, 48–56]. Interpretation of staining pattern
including the proportion of cells involved and robust
experimental methodology are critical to understanding the
role of Wnt signaling in serrated polyps.
The Wnt signal may also be altered by genetic or epi-
genetic targeting of other genes in the signaling pathway.
Integration of whole exome mutation and whole genome
copy number and gene expression data suggested over
90 % of BRAF mutant tumors have altered Wnt signal,
292 J Gastroenterol (2013) 48:287–302
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supporting a critical role in serrated as well as conventional
neoplasia [57]. The role of Wnt signaling in serrated polyps
may be further explored by examining genes in the path-
way that may be silenced by DNA hypermethylation. For
example, the Wnt pathway antagonists SFRP (types 1–5)
are commonly methylated in SSA and SSA with dysplasia,
but not in HP [46]. CDX2 is a transcription factor involved
in epithelial cell proliferation and differentiation that
inhibits the Wnt signal by binding b-catenin and disrupting
the b-catenin–TCF complex [58]. The CDX2 gene pro-
moter is methylated in SSA but not in HP or conventional
adenomas [46]. MCC is another Wnt pathway molecule
that directly interacts with b-catenin to dampen the Wnt
signal and this is also methylated in HP and SSA but
uncommonly in conventional adenomas [59].
p53 pathway alterations
The p53 tumor suppressor regulates cellular response to
stress through the cell cycle and apoptosis. Aberrant
nuclear accumulation of p53, which is suggestive of gene
mutation, correlates with dysplastic changes in a proportion
of SSAs and TSAs [41, 42]. Although no aberrant staining
was observed in 66 HPs or 53 SSAs, 6/12 SSAs with a
focus of dysplasia or cancer showed nuclear p53 accumu-
lation [41]. Furthermore, in these and another series of 6/24
TSAs showing aberrant staining, p53 accumulation was
limited to the dysplastic cells [41, 42]. Mutation of p53 is
uncommon in the serrated neoplasia pathway cancers
showing BRAF mutation, CIMP, and microsatellite insta-
bility, but is commonly mutated in the 50 % of BRAF
mutant, CIMP-positive cancers that do not methylate
MLH1 and are therefore microsatellite stable. It is possible
that MLH1 methylation and p53 mutation are critical
alterations leading to neoplastic change and transition to
either microsatellite unstable or microsatellite stable CRC,
respectively. IGFBP7 functions downstream of p53 to
mediate its tumor suppressor function [60]. In serrated
polyps that do not mutate p53, methylation of IGFBP7 may
be an alternate mechanism for inactivating the p53 path-
way. Interestingly, Kaji et al. [38] recently suggested that
whilst MLH1 and IGFBP7 methylation may often coexist
in serrated polyps, the order of events might be important
for directing the neoplastic pathway. They hypothesized
that primary methylation of IGFBP7 would result in TSA-




At colonoscopy, serrated lesions have a distinctive and
characteristic appearance. Hyperplastic polyps are the most
common serrated polyp subtype and are typically diminu-
tive and located in the distal colon and rectum [19]. They
are characteristically pale and flat or sessile, often with a
translucent appearance such that they can be less visible
with insufflation [61]. SSAs, which are typically larger than
HPs and located in the proximal colon, are flat or non-
polypoid in morphology [62], often with the appearance of
redundant or thickened mucosa altering the contour of a
fold, or appearing to be draped over a fold (Fig. 3) [63, 64].
A distinctive feature of SSAs is the mucus cap, comprising
a layer of mucus adherent to the surface of the lesion,
giving the lesion a yellow or rust-colored appearance in
contrast to the surrounding mucosa [65]. The mucus cap
assists in delineating the lesion from surrounding mucosa,
such that when removed with mucosal irrigation, the edges
of the lesion are indistinct and difficult to distinguish from
surrounding normal mucosa. These characteristics were
confirmed in a recent prospective study of 158 SSAs in
which dominant features included a mucus cap, a rim of
Fig. 3 Typical white light colonoscopic appearances of sessile serrated adenomas showing their flat appearance, draped over or thickening
mucosal folds, with characteristic mucus cap and/or rim of debris, alteration to background mucosal vascular pattern, indistinct border (a–c)
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bubbles or debris, alteration of the contour of a fold, and
loss of the normal mucosal vascular pattern (Table 3). TSA
are typically located distally, are more bulky, and tend to
be pedunculated or sessile [64].
Lesion characterization
Serrated lesions can be accurately and reliably distin-
guished from conventional adenomas during colonoscopy,
using real-time image-enhancement technologies that are
available on all current endoscopic platforms [66]. One
such technology is narrow-band imaging (NBI), which
utilizes a narrowed wavelength of light to highlight
mucosal microvasculature. A recently validated interna-
tional classification [67] for using NBI to determine real-
time histology indicates that serrated lesions appear the
same color or lighter than surrounding mucosa, have no
blood vessels or only isolated lacy blood vessels coursing
across the surface, and have no surface pattern or have dark
or white spots of uniform size (Fig. 4).
Real-time determination of serrated lesion subtype (SSA
vs. HP vs. TSA) based on mucosal and morphological
characteristics is limited, likely because the primary his-
tological characteristics of SSAs are located in the base of
the crypts [68]. Recent studies using optical magnification
colonoscopy (which is not widely available in Western
countries) have attempted to define endoscopic character-
istics of SSAs, to allow real-time differentiation [64, 69,
70]. Kimura et al. [69] found that a modification to the
Kudo pit-pattern classification, a novel type II-O (open)
pit-pattern was specific, but not sensitive for SSAs. How-
ever, Hasegawa et al. [64] found discrimination difficult
and instead relied on size and location of lesions. Fur-
thermore, areas of dysplasia within an SSA may theoreti-
cally be distinguishable at colonoscopy, particularly with
image enhancement techniques and/or optical magnifica-
tion (Fig. 5); however, this has not been studied.
Colonoscopic detection
Colonoscopy is not a perfect test, and multiple factors
contribute to the variable effectiveness of colonoscopy and
its possible limitations for lesion detection. These include
patient, technical, health system, and endoscopist factors,
such as adequacy of bowel preparation, equipment or
Fig. 4 Colonoscopic appearances of two sessile polyps with and
without image enhancement: sessile serrated adenoma with high
definition white light (a), NBI (narrow band imaging, Evis Exera II,
Olympus Medical Systems Corporation, Japan) (b), and indigocar-
mine dyespray chromocolonoscopy (c); sessile serrated adenoma with
white light (d), NBI (e), and with NBI after removal of mucus cap (f)
Table 3 Endoscopic features of sessile serrated adenomas (data from





Mucus cap 64 1.0




Alters fold contour 37 0.9
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reimbursement incentives, and variation in the motivation,
visuoperceptual capacity, and skills of the endoscopist
[71, 72].
In particular, colonoscopy is less effective at preventing
CRC in the proximal compared with the distal colon
[73–78]. It is hypothesized that this in part relates to fail-
ures to detect, recognize, and completely resect SSA
[79, 80]. Consistent with this hypothesis are data showing
that cancers occurring after colonoscopy are more likely to
be MSI-high and CIMP-high [81, 82], suggesting that they
originated in unrecognized SSAs and that exposure to
colonoscopy is associated with a lower risk of metachro-
nous advanced conventional adenomas in both the proxi-
mal and distal colon, but not SSAs [79].
Failures in detection and recognition of SSAs therefore
pose a major limitation of colonoscopy for CRC preven-
tion. In fact, variation in the detection of serrated polyps
between endoscopists is more substantial than the variation
in endoscopist detection of conventional adenomas
[83, 84]. Two studies now indicate the extent of this var-
iation and suggest that miss rates for serrated polyps are far
higher than for conventional adenomas. Specifically, Het-
zel et al. [83] analyzed 4,335 polyps from 7,192 average-
risk screening colonoscopies and found that proximal colon
SSA prevalence varied between endoscopists from 0 to
1.4 %. The prevalence of SSAs also increased over time,
from 0.2 % in 2006 to 1.1 % in 2008. Likewise, Kahi et al.
[84] found in 6,681 colonoscopies that proximal serrated
polyp prevalence (per colonoscopy) ranged between en-
doscopists from 1 to 26 %. As noted earlier, this variation
has implications for understanding the true prevalence of
SSA at colonoscopy.
Detection of serrated lesions is clearly operator-depen-
dent, indicating that specific knowledge and skills are
required for their detection and recognition. Lesion recog-
nition requires ‘‘target familiarity’’ with their characteristic
Fig. 5 Colonoscopic appearances of dysplastic and malignant serrated polyps: sessile serrated adenoma with dysplasia with white light (a) and
narrow band imaging (b); adenocarcinoma arising within a dysplastic sessile serrated adenoma in white light (c) and narrow band imaging (d)
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appearance, enabling the examiner to visually distinguish
the lesion from the background normal mucosa [85]. It
is likely that this requires extensive exposure to serrated
lesion appearances [65] and repeated, deliberate clinical
practice.
The role of specific colonoscopic technologies for
improving the detection of serrated lesions is unclear.
Studies of technologies to improve mucosal exposure at
colonoscopy (e.g., cap-fitted colonoscopy [86], proximal
colon retroflexion [87], and to improve recognition of
subtle lesions, e.g., high definition colonoscopy [88],
electronic image-enhancement [89], dyespray chromoen-
doscopy [90]) have not been specifically performed for
serrated lesion targets [19]. In the largest study of panco-
lonic chromocolonoscopy with indigocarmine dyespray,
Pohl et al. [91] found a significant increase in serrated
lesion detection (1.19 vs. 0.49 per patient). It is likely that
any beneficial impact of these technologies on serrated
polyp detection will be greater for those endoscopists with
lower baseline levels of polyp detection.
Management of patients with serrated polyps
Colonoscopic resection
Consensus recommendations are that all serrated lesions
should be removed at colonoscopy, except for diminutive
rectosigmoid hyperplastic polyps, which should be ran-
domly sampled for histology [68, 92]. Optimal resection
techniques are yet to be defined for serrated lesions,
although specific challenges relate to their morphology and
indistinct margins [93]. Cold snaring techniques (without
electrocautery) are generally recommended for lesions
under 10 mm [68, 94]. For larger lesions, electrocautery
with or without submucosal injection is warranted. Image-
enhancement techniques including NBI, topical dyespray
application, or submucosal dye injection (e.g., indigocar-
mine) may assist in delineating the margin of the lesion.
Early colonoscopic follow-up (at 3–6 months) is warranted
for piecemeal resection of larger serrated lesions given the
specific risks of incomplete resection with these lesions
[95] and reports of early interval cancer [96].
Surveillance
Management of SSAs and TSAs depends on understanding
their natural history particularly the transition to malignancy.
There is abundant evidence that these lesions are associated
with CRC [80, 97]. Perhaps more informative are studies of
lesions ‘‘caught in the act’’ of transition to malignancy
(Fig. 5). As discussed above, histological studies indicate
an abrupt transition from SSA to SSA with high-grade
cytological dysplasia and invasive malignancy and there is a
case report of this transition occurring in an 8-month time
period [98]. Three published case series show that the mean
size of such lesions is not much greater than the mean size of
typical SSAs without cytological dysplasia (Table 4).
Another study looked specifically at the median age of
patients with SSAs and found it to be 61 years for SSA,
72 years for SSAs with high-grade dysplasia, and 76 years for
patients presenting clinically with cancer related to an SSA
[99]. Furthermore, females were over-represented amongst
those patients with SSA progressing to high-grade dysplasia
and malignancy. Overall, these data suggest that SSA may be
present for many years with little change. However, in the
cases where invasive malignancy does develop, this happens
suddenly without a reliable window of warning signs such as
low-grade dysplasia or polyp size greater than 10 mm. This
interpretation of the data was also endorsed in recent con-
sensus reviews [68, 92]. It would be very helpful if molecular
or clinical markers able to predict which SSAs are most at risk
of progression could be developed.
So far there is limited evidence on which to base rec-
ommendations for surveillance in patients found to have
serrated polyps. In a group of 40 patients who had
‘‘hyperplastic polyps’’ removed between 1980 and 2001
whose polyps were SSAs on review and who were fol-
lowed up for a mean of 13.2 years, five developed sub-
sequent cancers and one had adenoma with high-grade
dysplasia [100]. At the time of the detection of the SSA,
these patients had no history of adenomas or cancer and so
would not have been recommended to have surveillance
according to the guidelines at the time. In another study, 39
patients were identified on colonoscopy between 1994 and
1997 as having proximal non-dysplastic serrated polyps as
the only lesion in their bowel and underwent further
colonoscopy within 5.5 years [97]. These patients had a
3.14-fold increased risk of adenoma during follow-up
compared to control patients with no polyps.
Table 4 Summary of studies reporting the mean size of sessile ser-




























SSA sessile serrated adenoma
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A more recent study reported on 22 patients found to
have at least one SSA at colonoscopy in 2005 [101]. Many
but not all of these patients had synchronous adenomas or a
history of prior polyps. Follow-up colonoscopy over the
next 5 years found new SSAs in 11 (50 %) of these
patients. Two of the SSAs displayed low-grade dysplasia
and one high-grade dysplasia. Adenomas were found in
45 % of patients and one patient developed CRC. Another
study published in 2012 reported 43 patients with at least
one SSA diagnosed on colonoscopy between 2002 and
2004 with follow-up colonoscopy [102]. At an average of
2.72 years after the initial colonoscopy, SSAs were found
in 22 patients (51 %), adenomas in 16 patients (37 %),
SSA with high-grade dysplasia in 1 patient, and mucinous
carcinoma developed in 1 patient.
Colonoscopy is an excellent tool to prevent CRC but it
is costly, invasive, and carries some risk. Thus surveillance
colonoscopy in patients known to be at risk aims to be
frequent enough to detect lesions prior to malignant
transformation but not unnecessarily frequent. To date,
most national guidelines for colonoscopy surveillance after
polypectomy agree that patients with small, distally located
hyperplastic polyps do not require subsequent surveillance
[68, 92, 103]. They recognized that other serrated lesions
are significant but note that there is limited evidence to
make firm recommendations.
Factors which may guide surveillance intervals include:
– Histologic subtype: SSA and TSA are certainly
predictive of a higher risk than HPs. It is likely that
the presence of low-grade or high-grade cytological
dysplasia in a SSA or TSA further heightens the risk of
subsequent significant lesions.
– Number of polyps: Almost certainly the risk of
subsequent polyps and cancer increases with the
number of polyps and the most extreme example of
this is serrated polyposis where it is agreed that the
surveillance interval should be 1 year [68].
– Concomitant conventional adenomas: There is no
direct evidence but it is likely that patients with a
higher polyp burden due to the presence of both
adenomas and serrated polyps are at greater risk.
– Location in the colon: Most cancers arising in serrated
polyps do so in the proximal colon. However most
SSAs are themselves in the proximal colon and it is not
certain whether the uncommon SSAs occurring in the
distal colon are individually of less risk.
– Size of polyps: It is likely that there is an increased
risk in patients with larger SSAs but it is not clear that
the cutoff of 10 mm used to define advanced
conventional adenomas applies to SSAs. SSAs rarely
grow larger than 20 mm [104] and most large polyps
are adenomas. As discussed above, the average size of
SSAs shown to contain invasive malignancy ranged
from 8 to 11 mm.
The recently published guidelines shown in Table 5 were
based on consensus expert opinion [68]. They are based on
the premise that the colonoscopy is of good quality with a
high detection rate of serrated lesions and that all serrated
lesions are fully resected except for the most diminutive
hyperplastic polyps in the distal bowel. They are also based
on the premise that pathological interpretation of the lesions
is consistent with the current WHO guidelines as described
above. If there is doubt about the latter, a conservative
position is to consider all proximal serrated lesions larger
than 10 mm as SSAs even if they are reported as HPs [105].
These guidelines were endorsed in a simplified form in the
2012 American Gastroenterological Association guidelines
for colonoscopy surveillance after screening and polypec-
tomy [92]. It is recommended that patients with SSAs
smaller than 10 mm and without dysplasia be followed up
at 5 years and patients with TSAs or SSAs of at least 10 mm
or with dysplasia be followed up at 3 years.
Serrated polyposis
Serrated polyposis syndrome (SPS) is the WHO’s pre-
ferred terminology for the condition previously called
Table 5 Current guidelines for colonoscopy surveillance after diag-





Number Location Surveillance interval
(years)
HP \10 Any Rectosigmoid Population screening
HP B5 B3 Proximal to
sigmoid
Population screening
HP Any C4 Proximal to
sigmoid
5





\10 \3 Any 5
SSA or
TSA
C10 Any Any 3
SSA or
TSA
\10 C3 Any 3
SSA or
TSA
C10 C2 Any 1–3 (serrated
polyposis if 3
additional serrated





Any Any Any 1–3
HP hyperplastic polyp, SSA sessile serrated adenoma, TSA traditional
serrated adenoma
J Gastroenterol (2013) 48:287–302 297
123
hyperplastic polyposis. The term SPS emphasizes the
common occurrence of sessile serrated adenoma. Patients
fulfilling one or more of the current following criteria are
diagnosed with SPS: (1) at least five serrated polyps
proximal to the sigmoid colon with two or more of these
being larger than 10 mm; (2) any number of serrated pol-
yps proximal to the sigmoid colon in an individual who had
a first-degree relative with SP; (3) more than 20 serrated
polyps of any size but distributed throughout the colon
[21]. In practice, criterion 2 is rarely used. The number of
polyps is cumulative over time. There has been recent
interest in this syndrome with studies emphasizing the lack
of awareness and the under-recognition of SPS among
gastroenterologists and pathologists [106–109]. SPS is
characterized by a continuum of phenotypes with polyposis
commonly affecting the entire large bowel and the frequent
co-occurrence of conventional adenoma (Fig. 6) [110]. The
prevalence of SPS may be as high as 1/151 patients
undergoing colonoscopy after positive fecal occult blood
test [106]. Patients with SPS are at increased risk for CRC
with the actual risk yet to be defined from prospective
studies [111]. First-degree relatives are also at increased
risk of CRC [112, 113], justifying the recommendation for
screening colonoscopy in first-degree relatives aged at least
40 years or aged 10 years younger than the age of diag-
nosis of the youngest relatives [68, 114]. Further colon-
oscopy is recommended at 5-year intervals or more
frequently if polyps are detected. The recommended
colonoscopy surveillance interval in SPS patients is yearly
with the aim to remove all polyps over 5 mm in size.
Surgery is indicated when CRC is diagnosed or when a
high polyp burden cannot be controlled by colonoscopy.
Until a genetic hallmark of SPS is identified, the criteria for
the diagnosis and the surveillance of this syndrome remain
rather arbitrary.
Conclusions and perspectives
Serrated polyps comprise a diverse group of polyps with
common morphological serrated appearance and distinct
endoscopic, histological, and molecular profiles. There is
growing evidence that interval CRCs in the proximal colon
are caused by serrated polyps missed at colonoscopy. This
represents a challenge for gastroenterologists to improve
the detection rate of sessile polyps, many of which will be
SSAs, by increased awareness and the use of advanced
imaging techniques. Likewise pathologists should become
more familiar with the histological features that distinguish
SSA from HP and should use the WHO criteria to correctly
diagnose serrated polyp subtypes. Because interobserver
variability in histological diagnosis still exists, many
experts consider that all serrated polyps in the proximal
colon larger than 10 mm in size are likely to be SSAs, even
if pathologists interpret them as HPs. The rarer lesion of
TSA is still poorly understood and requires additional
studies to refine criteria for diagnosis and understanding of
the molecular heterogeneity of this polyp subtype. TSAs
with KRAS mutation may have different malignant poten-
tial than TSAs with BRAF mutation. The recent availability
of an antibody that reliably detects BRAF mutation by
immunohistochemistry may help in identifying serrated
polyps and move towards a more molecularly based clas-
sification of colorectal polyps [119]. Detection of BRAF
mutation may be particularly helpful in distinguishing SSA
with extensive cytological dysplasia from conventional
adenoma as these two polyps are likely to have different
malignant potential. Serrated polyposis may be more pre-
valent than initially thought now that gastroenterologists
and pathologists have become more aware of this condi-
tion. However, prospective studies are needed to assess the
risk of CRC and metachronous polyps in patients diag-
nosed with serrated polyps and serrated polyposis. Until
then, the colonoscopy surveillance guidelines are based
only on a low level of evidence.
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